EDUCATIONAL NOTICE: Peptidings provides information for educational and research purposes only. The compounds in this research cluster are subjects of ongoing scientific investigation at varying stages of development. None of the information presented here constitutes medical advice or a recommendation for use. Consult a qualified healthcare provider before making any decisions about peptide use.
Research Cluster
Gut Health Peptides
Gut health peptides directly regulate gastrointestinal function—from appetite signaling and nutrient absorption to intestinal barrier integrity and mucosal repair.
Unusually for a peptide cluster, three of five compounds here are FDA-approved drugs with well-established clinical applications. The evidence base is strong but narrowly focused on specific GI conditions.
Cluster at a Glance
|
5 Compounds Covered |
3 Approved Drug |
2 Clinical Trials |
|
Approved Drug FDA-approved or equivalent regulatory approval |
Clinical Trials Human clinical trial data (Phase I+) |
BLUF: Bottom Line Up Front
Three approved drugs (CCK, GLP-2/Teduglutide, Secretin) with well-defined clinical roles, plus two clinical-stage compounds (Ghrelin, Larazotide) targeting unmet needs in gastroparesis and celiac disease. This is one of the most pharmaceutically mature gut-focused clusters, but the approved compounds serve narrow indications—Teduglutide for short bowel syndrome, Secretin for pancreatic function testing, and CCK as a diagnostic tool. Larazotide is the most interesting pipeline compound: a first-in-class tight junction regulator for celiac disease that could change how we think about intestinal permeability.
In This Article
Compounds in This Cluster
All 5 compounds in the Gut Health Peptides cluster, organized by mechanism and editorial function. Each grouping reflects how these compounds relate to each other scientifically—not just alphabetically.
Group 1 of 2
The Approved GI Drugs
FDA-approved peptides with established clinical roles in gastrointestinal medicine.
Group 2 of 2
The Clinical Pipeline
Compounds with substantial human trial data targeting unmet gastrointestinal needs.
|
|
How These Compounds Relate
The five compounds in this cluster regulate distinct aspects of gastrointestinal physiology. GLP-2/Teduglutide directly stimulates intestinal epithelial growth—it is the only approved drug that can make the gut lining physically regenerate. CCK and Secretin operate upstream as digestive coordinators: CCK triggers gallbladder contraction and enzyme release, while Secretin manages the acid-base balance that protects the intestinal mucosa.
Ghrelin works through a completely different axis—the gut-brain hunger signaling pathway. Its clinical applications focus on restoring motility and appetite in conditions where the stomach has essentially stopped moving (gastroparesis) or the body has lost its drive to eat (cachexia). Larazotide represents the newest mechanistic approach in this cluster: rather than stimulating growth or motility, it prevents damage by reinforcing the tight junctions between intestinal cells that gluten disrupts in celiac disease.
What connects these compounds is their shared target organ, not their shared mechanism. Each addresses a different failure mode of the GI tract—insufficient mucosal growth, impaired digestive coordination, lost motility, or compromised barrier function.
| Shared Mechanism | Compounds |
|
Intestinal Mucosal Growth Directly stimulates proliferation of intestinal epithelial cells to regenerate and adapt the gut lining. |
GLP-2 / Teduglutide |
|
Digestive Coordination Regulates gallbladder contraction, pancreatic enzyme secretion, and acid-base balance for proper nutrient processing. |
Cholecystokinin (CCK), Secretin |
|
Gastric Motility / Appetite Signaling Activates the GHS-R1a receptor to accelerate gastric emptying and restore hunger signaling. |
Ghrelin |
|
Tight Junction Regulation Stabilizes intestinal barrier integrity by preventing zonulin-mediated tight junction disassembly. |
Larazotide |
Plain English
Five peptides, five different jobs in your gut. One makes the gut lining grow back (Teduglutide). Two coordinate digestion—triggering bile and enzymes when food arrives (CCK and Secretin). One tells your brain you are hungry and gets your stomach moving again (Ghrelin). And one seals the gaps between intestinal cells that gluten pries open in celiac disease (Larazotide). Three are already approved drugs; the other two are in clinical trials. This is not a speculative cluster—these are compounds with real medical applications.
Stay Current
New research, new articles, no noise
Peptidings publishes long-form peptide research articles grounded in primary literature. Subscribe to get new compound articles, cluster updates, and evidence reviews delivered to your inbox.
Disclaimer: This page is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. The compounds discussed are subjects of ongoing scientific research and have not been evaluated by the FDA for all applications described. Consult a qualified healthcare provider before making any decisions about your health.